- About us
- Clinical trials
- News & Publications
Antibody-drug conjugates (ADCs) are one of the most actively pursued therapeutic classes in oncology due to their high specificity and potency. The conjugates have two components: an antibody allowing the delivery of drug to tumors in a highly targeted manner, and a potent cytotoxic agent to directly kill tumor cells.
Despite the high degree of specificity and potency for ADCs, there are continued challenges that limit their success:
SOTIO’s ADC platform, which is being developed in partnership with NBE-Therapeutics, is based on NBE’s proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform. The ADCs utilize an anthracycline toxin called PNU, a highly potent cytotoxic agent derived from doxorubicin, that leads to immunogenic cell death and elicits a long-lasting immune response.
SOTIO’s ADCs have been designed to address the limitations of current ADCs: